Abstract:Background and purpose: The pathophysiological features of acute ischemic stroke (AIS) often involve dysfunction of the blood-brain barrier (BBB), characterized by the degradation of tight junction proteins (Tjs) leading to increased permeability. This dysfunction can exacerbate cerebral injury and contribute to severe complications. The permeability of the BBB fluctuates during different stages of AIS and is influenced by various factors. Developing effective therapies to restore BBB function remains a significant challenge in AIS treatment. High levels of vascular endothelial growth factor (VEGF) in the early stages of AIS have been shown to worsen BBB breakdown and stroke progression. Our study aimed to investigate the protective effects of the VEGF receptor inhibitor Axitinib on BBB dysfunction and cerebral ischemia/reperfusion-induced injury. Methods: BEnd3 cell exposed to oxygen-glucose deprivation (OGD) model was constructed to estimate pharmacological activity of Axitinib (400 ng/ml) on anti-apoptosis and pathological barrier function recovery. In vivo, rats were subjected to a 1 h transient middle cerebral artery occlusion and 23 h reperfusion (tMCAO/R) to investigate the permeability of BBB and cerebral tissue damage. Axitinib was administered through the tail vein at the beginning of reperfusion. BBB integrity was assessed by Evans blue leakage and the expression levels of Tjs claudin-5 and occludin. Results: Our research revealed that co-incubation with Axitinib enhanced the cell viability of OGD-insulted bEnd3 cells, decreased LDH leakage rate, and suppressed the expression of apoptosis-related proteins cytochrome C and Bax. Axitinib also mitigated the damage to Tjs and facilitated the restoration of transepithelial electrical resistance in OGD-insulted bEnd.3 cells. In vivo, Axitinib administration reduced intracerebral Evans blue leakage and up-regulated the expression of Tjs in the penumbra brain tissue in tMCAO/R rats. Notably, 10 mg/kg Axitinib exerted a significant anti-ischemic effect by decreasing cerebral infarct volume and brain edema volume, improving neurological function, and reducing pro-inflammatory cytokines IL-6 and TNF-alpha in the brain. Conclusions: Our study highlights Axitinib as a potent protectant of blood-brain barrier function, capable of promoting pathological blood-brain barrier recovery through VEGF inhibition and increased expression of tight junction proteins in AIS. This suggests that VEGF antagonism within the first 24 h post-stroke could be a novel therapeutic approach to enhance blood-brain barrier function and mitigate ischemia-reperfusion injury.

Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy

Cation flux through SUR1-TRPM4 and NCX1 in astrocyte endfeet induces water influx through AQP4 and brain swelling after ischemic stroke

Microglia: A Potential Drug Target for Traumatic Axonal Injury

The Protective Effects of Axitinib on Blood-Brain Barrier Dysfunction and Ischemia-Reperfusion Injury in Acute Ischemic Stroke

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

The SWELL1 Channel Promotes Ischemic Brain Damage by Mediating Neuronal Swelling and Glutamate Toxicity

Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury

Astrocyte TrkB promotes brain injury and edema formation in ischemic stroke

Neuronal Injury in Rat Model of Permanent Focal Cerebral Ischemia is Associated with Activation of Autophagic and Lysosomal Pathways.

Key Players in Astrocyte Regulatory Volume Reduction (RVD): VRAC and Aquaporin

Astrocytic TRPV4 Channels and Their Role in Brain Ischemia

Loss of astrocyte polarization upon transient focal brain ischemia as a possible mechanism to counteract early edema formation

Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

Drug Discovery Research for Traumatic Brain Injury Focused on Functional Molecules in Astrocytes

Effect of Tetrahedral Framework Nucleic Acids on Neurological Recovery via Ameliorating Apoptosis and Regulating the Activation and Polarization of Astrocytes in Ischemic Stroke

Astrocyte-TREM2 alleviates brain injury by regulating reactive astrocyte states following ischemic stroke

Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4

Blocking Formation of Neurotoxic Reactive Astrocytes is Beneficial Following Stroke

Emerging therapeutic targets for cerebral edema

Spatiotemporally selective ATP events from astrocytes encode injury information and guide sustained microglial response

Molecular targets in cerebral ischemia for developing novel therapeutics